[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583020":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":40,"centralContacts":44,"locations":50,"responsibleParty":67,"collaborators":11,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":11,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":94,"overallStatus":95,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University Hospital, Clermont-Ferrand","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All the patient included in the study","EXPERIMENTAL",null,[13,14,15,16],"Diagnostic Test: muscle evaluation","Biological: Dosage","Diagnostic Test: Cardiopulmonary exercise test","Combination Product: Questionnaire and Physical Exam",[18,23,31,35],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DIAGNOSTIC_TEST","muscle evaluation","The investigators will evaluate the muscle mass and muscle strenght for all patients included",[9],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"BIOLOGICAL","Dosage","Evaluation of the cinetic of biomarkers during exercise",[9],[29,30],"Others dosages at rest only","Dosage of biomarkers at rest and after exercise",{"type":19,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"Cardiopulmonary exercise test","CPET",[9],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"COMBINATION_PRODUCT","Questionnaire and Physical Exam","Evaluating dyspnea, anxiety, sleep, physical activity, quality of life",[9],[41],{"name":42,"affiliation":5,"role":43},"Camille ROLLAND-DEBORD","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Lise Laclautre","CONTACT","334.73.754.963","promo_interne_drci@chu-clermontferrand.fr",[51],{"facility":52,"status":11,"city":53,"state":11,"zip":11,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"CHU Clermont-Ferrand","Clermont-Ferrand","France","FR",{"type":57,"coordinates":58},"Point",[59,60],3.08682,45.77969,{"lat":60,"lon":59},[63,66],{"name":64,"role":47,"phone":65,"phoneExt":11,"email":49},"Lise LACLAUTRE","+33473754963",{"name":42,"role":43,"phone":11,"phoneExt":11,"email":11},{"type":68,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100583020","impact-of-sarcopenia-on-dyspnea-in-patients-with-asthma-100583020",false,"NCT06870890","Impact of Sarcopenia on Dyspnea in Patients With Asthma","MUDYSA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient affiliated to a social security scheme.\n* Patient capable of giving free, informed, written and signed consent.\n* Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment\n* ACT asthma control score \\\u003C 20\n* Patient judged by the investigator to be able to to perform a maximal exercise test.\n\nExclusion Criteria:\n\n* Patient under guardianship\u002Ftrusteeship\u002Fsupervision of justice\n* Pregnant or breast-feeding women\n* Unstable heart disease\n* Patients who have been smoking or have stopped smoking for less than 5 years,","ALL","18 Years",{"count":79,"type":80},100,"ESTIMATED","INTERVENTIONAL",[83],"NA","Dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses.\n\nThe impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea .\n\nThe morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction.\n\nThe investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.",[86,87,88,89,90,91,92,93],"Sarcopenia","Asthma","Dyspnea","Dyspnea; Asthmatic","Cytokines","Adipokines","Myokine","Muscle Disorder",[87,86,88],"NOT_YET_RECRUITING","2025-03-10",{"date":98,"type":99},"2025-03-11","ACTUAL",{"date":101,"type":80},"2025-03-25",{"date":103,"type":80},"2026-10",{"name":5,"class":6},1]